Dapagliflozin in Patients with HF and HFrEF


This method paper details the DAPA-HF trial. The ground-breaking DAPA-HF trial showed that among patients with HF and a HFrEF, those who received the SGLT2i dapagliflozin had a lower risk of worsening HF or death from CV causes, regardless of the presence or absence of diabetes.

McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med 2019;381:1995–2008.